Silence Therapeutics PLC (NAS:SLN)

$ 22.94 0.61 (2.73%) Market Cap: 1.07 Bil Enterprise Value: 1.00 Bil PE Ratio: 0 PB Ratio: 40.25 GF Score: 49/100

Full Year 2021 Silence Therapeutics PLC Earnings Call Transcript
Mar 17, 2022

$16.71 (-1.71%)

Earnings
Silence Therapeutics PLC Corporate Call Transcript
Oct 21, 2021
Silence Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Half Year 2021 Silence Therapeutics PLC Earnings Call Transcript
Aug 12, 2021

$25.73

Earnings
Silence Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2021
Full Year 2020 Silence Therapeutics PLC Earnings Call Transcript
Mar 30, 2021

$22.95

Earnings
Silence Therapeutics PLC at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
Silence Therapeutics PLC at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Silence Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Half Year 2020 Silence Therapeutics PLC Earnings Call Transcript
Sep 14, 2020

$19.5

Earnings
Full Year 2019 Silence Therapeutics PLC Earnings Call Transcript
Apr 14, 2020

Earnings
Silence Therapeutics PLC Collaboration With AstraZeneca and R&D Update Call Transcript
Mar 25, 2020
Silence Therapeutics PLC and Mallinckrodt Plc Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases Transcript
Jul 18, 2019

Silence Therapeutics PLC Corporate Call Transcript

Oct 21, 2021 / 01:00PM GMT

Release Date Price: $22.7

Transcript

Gem Gokmen Hopkins

Silence Therapeutics plc - Head of IR & Corporate Communications

(technical difficulty)

Dr. Tom Ganz from the David Geffen School of Medicine at UCLA, who will discuss the key role of hepcidin in iron regulation and its therapeutic potential. From our London site, we have our Head of R&D and Chief Medical Officer; Dr. Giles Campion, who will provide an update on our SLN124 hepcidin regulation program.

Additionally, we are excited to have Dr. Henry Ginsberg, Irving Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Ginsberg will share an overview of the medical need in cardiovascular disease. Following his presentation, Giles will give an update on our SLN360 program for cardiovascular disease due to high lipoprotein(a). Mark will then provide some concluding remarks and moderate a Q&A session at the end of the meeting or at the end of the presentation.

If you would like to submit a question, you can do so at any time during the meeting by typing your questions in the Ask a Question field on the right side of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.